Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Price:
30.42 USD
-1.33%
Market Closed
Updated:
May 7, 2024
Supernus Pharmaceuticals Inc
Operating Income
|
Supernus Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
Operating Income
$14.9m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$24.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$10.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$11.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
See Also
What is Supernus Pharmaceuticals Inc's Operating Income?
Operating Income
14.9m
USD
14.9m
USD
Based on the financial report for Dec 31, 2023, Supernus Pharmaceuticals Inc's Operating Income amounts to 14.9m USD.
What is Supernus Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-36%
-36%
Over the last year, the Operating Income growth was -68%. The average annual Operating Income growth rates for Supernus Pharmaceuticals Inc have been -57% over the past three years , -36% over the past five years .
You don't have any saved screeners yet
